Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

Lipocine to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference
 Monday, October 21, 2019
 2:40pm - 3:40pm EDT